Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

Breast Cancer Research and Treatment

Volumn 119, Issue 2, 2010, Pages 379-390

  Ellis, Matthew J ^a,b   Lin, Li ^a,b   Crowder, Robert ^a,b   Tao, Yu ^a,b   Hoog, Jeremy ^a,b   Snider, Jacqueline ^a,b   Davies, Sherri ^a,b   Deschryver, Katherine ^a,b   Evans, Dean B ^c   Steinseifer, Jutta ^c   Bandaru, Raj ^d   Liu, Weihua ^d   Gardner, Humphrey ^d   Semiglazov, Vladimir ^e   Watson, Mark ^a,b   Hunt, Kelly ^f   Olson, John ^g   Baselga, José ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

Estrogen receptor positive breast cancer; Neoadjuvant endocrine therapy; Phosphatidyl inositol 3 kinase; Prognosis; Somatic mutation

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; LETROZOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PROTEIN KINASE B; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CATALYSIS; CONTROLLED STUDY; EXON; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HORMONAL THERAPY; HUMAN; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MUTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 74849112055     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0575-y     Document Type: Article

References (17)

1. Y Samuels Z Wang A Bardelli, et al. 2004 High frequency of mutations of the PIK3CA gene in human cancers Science 304 5670 554 10.1126/science.1096502 1:CAS:528:DC%2BD2cXjsVGmsbk%3D 15016963 (Pubitemid 38541907)
2. LH Saal K Holm M Maurer, et al. 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Res 65 7 2554 2559 10.1158/0008-5472-CAN-04-3913 1:CAS:528:DC%2BD2MXjtVeqsrc%3D 15805248 (Pubitemid 40490050)
3. G Perez-Tenorio L Alkhori B Olsson, et al. 2007 PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer Clin Cancer Res 13 12 3577 3584 10.1158/1078-0432.CCR-06-1609 1:CAS:528:DC%2BD2sXmsFCqtbk%3D 17575221 (Pubitemid 46955118)
4. K Stemke-Hale AM Gonzalez-Angulo A Lluch, et al. 2008 An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer Cancer Res 68 15 6084 6091 10.1158/0008-5472.CAN-07-6854 1:CAS:528:DC%2BD1cXpt1SqtLs%3D 18676830
5. K Kalinsky LM Jacks A Heguy, et al. 2009 PIK3CA mutation associates with improved outcome in breast cancer Clin Cancer Res 15 16 5049 5059 10.1158/1078-0432.CCR-09-0632 1:CAS:528:DC%2BD1MXpvFeis78%3D 19671852
6. M Barbareschi F Buttitta L Felicioni, et al. 2007 Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas Clin Cancer Res 13 20 6064 6069 10.1158/1078-0432.CCR-07-0266 1:CAS:528:DC%2BD2sXhtFygs7nL 17947469 (Pubitemid 350075063)
7. ON Ikediobi H Davies G Bignell, et al. 2006 Mutation analysis of 24 known cancer genes in the NCI-60 cell line set Mol Cancer Ther 5 11 2606 2612 10.1158/1535-7163.MCT-06-0433 1:CAS:528:DC%2BD28Xht1els7jK 17088437 (Pubitemid 44848987)
8. RJ Crowder C Phommaly Y Tao, et al. 2009 PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer Cancer Res 69 9 3955 3962 10.1158/0008-5472.CAN- 08-4450 1:CAS:528:DC%2BD1MXltFOksbo%3D 19366795
9. MJ Ellis A Coop B Singh, et al. 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 18 3808 3816 1:CAS:528:DC%2BD3MXnsVKqsbo%3D 11559718
10. J Baselga V Semiglazov P van Dam, et al. 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2630 2637 10.1200/JCO.2008.18.8391 1:CAS:528:DC%2BD1MXnslWit7s%3D 19380449
11. JA Olson Jr GT Budd LA Carey, et al. 2009 Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial J Am Coll Surg 208 5 906 914 10.1016/j.jamcollsurg.2009.01.035 19476859 discussion 15-6
12. MJ Ellis A Coop B Singh, et al. 2003 Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status Cancer Res 63 19 6523 6531 1:CAS:528:DC%2BD3sXotV2isLw%3D 14559846
13. MJ Ellis Y Tao O Young, et al. 2006 Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole J Clin Oncol 24 19 3019 3025 10.1200/JCO.2005.04.3034 1:CAS:528:DC%2BD28XnslKhsrY%3D 16754938 (Pubitemid 46638935)
14. V Serra B Markman M Scaltriti, et al. 2008 NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3 K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 68 19 8022 8030 10.1158/0008-5472.CAN-08- 1385 1:CAS:528:DC%2BD1cXhtF2msLrK 18829560
15. MJ Ellis Y Tao J Luo, et al. 2008 Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics J Natl Cancer Inst 100 19 1380 1388 10.1093/jnci/djn309 1:CAS:528:DC%2BD1cXht1Sitb7F 18812550
16. R Marone V Cmiljanovic B Giese MP Wymann 2008 Targeting phosphoinositide 3-kinase: moving towards therapy Biochim Biophys Acta 1784 1 159 185 1:CAS:528:DC%2BD1cXptlerug%3D%3D 17997386
17. S Di Cosimo J Baselga 2009 Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation? Clin Cancer Res 15 16 5017 5019 10.1158/1078-0432.CCR-09-1173 1:CAS:528:DC%2BD1MXpvFeisro%3D 19671849